Company intelligence / Profile preview

Quthero

Florida, United Statesquthero.com ↗
Ownership
Private
Development stage
Other
01

Overview

Quthero is advancing regenerative therapies using its proprietary Q-peptide technology, with pre-clinical evidence supporting enhanced cell survival, anti-inflammatory, and regenerative effects, particularly in skin and cardiovascular tissues. Their platform is designed to promote rapid, healthy wound closure with minimal scarring. The company is also developing a post-procedure skincare line under the Kerra brand.

Therapeutic areas
Dermatology
Modalities
PeptidesHydrogel-based drug delivery therapy
Industry
Biotech
02

Drug pipeline

4 assets

Kerra

2

3 more assets in the full pipeline.

Beyond the preview

Go deeper on Quthero.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quthero.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call